About Compass Therapeutics Inc.
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.compasstherapeutics.com/
Frequently Asked Questions
What is the 52-week range for CMPX?
The 52-week high is $6.88 and the 52-week low is $0.9009.
What is the P/E ratio for CMPX?
The P/E ratio data is currently unavailable.
What is the dividend yield for CMPX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -29.94%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.85.
Analyst Recommendation Trends
Wall Street analyst consensus for CMPX over the last few months:
Latest CMPX News
Curious about the stocks that are showing activity after the closing bell on Friday?
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’
Several analysts slashed their price targets on Compass Therapeutics after the FDA requested an additional trial for its cancer drug.
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8
Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity
Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. Read more on CMPX stock here.
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4
Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4
Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1
Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.
HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Lowers Price Target to $12
HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $24 to $12.
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
Compass said on Tuesday that the FDA recommended a trial showing a survival benefit before the company files a biologics license application for tovecimig in previously treated advanced biliary tract cancer.
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 0.5% and the St
Which stocks are experiencing notable movement on Tuesday?
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program. The move is coming even as S&P 500 futures are up 0.1%, pointing to stock-specific pressure rather than a broad risk-off tape. Read Also: Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care CMPX Stock Drops After FDA Feedback On Tovecimig BLA Path Compass said the FDA recommended the company run a t
What's going on in today's session
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing
The FDA wants Compass to conduct a trial showing Tovecimig can improve overall survival in patients with previously treated, advanced biliary tract cancer.
Gapping stocks in Tuesday's session
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved upwards by
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig.Compass does not believe that a new trial is warranted prior to submitting a BLA based on the data from the Phase 2/3 COMPANION-002 study and the urgent unmet medical need for patients with BTC.Compass intends to further engage with the FDA as we continue to prepare a BLA submission for tovecimig. Compass remains confident in tovecimig based on the positive results from COMP
Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings
U.S. stocks rose Tuesday: Dow +0.24%, Nasdaq +0.39%, S&P 500 +0.18%. Communication services led; energy fell. AutoZone beat earnings; oil dropped 2.4%.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-24 | Lerner Neil | +2,500 | $1.14 | $2,850 |
| 2026-04-29 | Anderman Jonathan | +25,000 | $1.89 | $47,250 |
| 2026-04-29 | Lerner Neil | +15,000 | $1.89 | $28,350 |
| 2026-02-08 | Schuetz Thomas J. | -36,687 | $6.52 | $239,199 |
| 2026-01-09 | Schuetz Thomas J. | -46,777 | $5.35 | $250,257 |
| 2026-01-02 | Shin Barry | +670,000 | - | - |
| 2026-01-02 | Shin Barry | +125,000 | $5.17 | $646,250 |
| 2026-01-02 | Sirard Cynthia | +1,000,000 | - | - |
| 2026-01-02 | Prasad Arjun | +1,000,000 | - | - |
| 2026-01-02 | Boylan James P | +90,000 | - | - |
| 2026-01-02 | Ferneau Philip | +90,000 | - | - |
| 2026-01-02 | Anderman Jonathan | +720,000 | - | - |
| 2026-01-02 | Anderman Jonathan | +150,000 | $5.17 | $775,500 |
| 2026-01-02 | Schuetz Thomas J. | +2,000,000 | - | - |
| 2026-01-02 | Schuetz Thomas J. | +250,000 | $5.17 | $1,292,500 |
| 2026-01-02 | Lerner Neil | +435,000 | - | - |
| 2026-01-02 | Lerner Neil | +62,500 | $5.17 | $323,125 |
| 2026-01-02 | Chiniara Ellen | +90,000 | - | - |
| 2026-01-02 | GORDON CARL L | +90,000 | - | - |
| 2026-01-02 | GRAY MARY ANN | +90,000 | - | - |
| 2026-01-02 | LINDAHL RICHARD S | +90,000 | - | - |
| 2025-11-16 | Schuetz Thomas J. | -44,025 | $4.83 | $212,641 |